{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["aceclofenac nanocrystals", "dissolution rate", "in vivo studies", "precipitation\u2013ultrasonication"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "28860715", "DateCompleted": {"Year": "2018", "Month": "05", "Day": "10"}, "DateRevised": {"Year": "2022", "Month": "04", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "08", "Day": "23"}], "Language": ["eng"], "ELocationID": ["10.2147/DDDT.S140626"], "Journal": {"ISSN": "1177-8881", "JournalIssue": {"Volume": "11", "PubDate": {"Year": "2017"}}, "Title": "Drug design, development and therapy", "ISOAbbreviation": "Drug Des Devel Ther"}, "ArticleTitle": "Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: formulation optimization, characterization, analgesic and acute toxicity studies.", "Pagination": {"StartPage": "2443", "EndPage": "2452", "MedlinePgn": "2443-2452"}, "Abstract": {"AbstractText": ["This study was aimed to enhance the dissolution rate, oral bioavailability and analgesic potential of the aceclofenac (AC) in the form of nanosuspension using cost-effective simple precipitation-ultrasonication approach. The nanocrystals were produced using the optimum conditions investigated for AC. The minimum particle size (PS) and polydispersity index was found to be 112\u00b12.01 nm and 0.165, respectively, using hydroxypropyl methylcellulose (1%, w/w), polyvinylpyrrolidone K30 (1%, w/w) and sodium lauryl sulfate (0.12%, w/w). The characterization of AC was performed using zeta sizer, scanning electron microscopy, transmission electron microscopy, powder X-ray diffraction and differential scanning calorimetry. The saturation solubility of the AC nanocrystals was substantially increased 2.6- and 4.5-fold compared to its unprocessed active pharmaceutical ingredient in stabilizer solution and unprocessed drug. Similarly, the dissolution rate of the AC nanocrystals was substantially enhanced compared to its other counterpart. The results showed that >88% of AC nanocrystals were dissolved in first 10 min compared to unprocessed AC (8.38%), microsuspension (66.65%) and its marketed tablets (17.65%). The in vivo studies of the produced stabilized nanosuspension demonstrated that the C<sub>max</sub> were 4.98- and 2.80-fold while area under curve from time of administration to 24 h (AUC<sub>0\u219224 h</sub>) were found 3.88- and 2.10-fold greater when compared with unprocessed drug and its marketed formulation, respectively. The improved antinociceptive activity of AC nanocrystals was shown at much lower doses as compared to unprocessed drug, which is purely because of nanonization which may be attributed to improved solubility and dissolution rate of AC, ultimately resulting in its faster rate of absorption."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, University of Malakand, Chakdara."}], "LastName": "Rahim", "ForeName": "Haroon", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, University of Malakand, Chakdara."}], "LastName": "Sadiq", "ForeName": "Abdul", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, University of Malakand, Chakdara."}], "LastName": "Khan", "ForeName": "Shahzeb", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, University of Malakand, Chakdara."}], "LastName": "Khan", "ForeName": "Mir Azam", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, Sarhad University of Science and Information Technology Peshawar, Khyber Pakhtunkhwa, Pakistan."}], "LastName": "Shah", "ForeName": "Syed Muhammad Hassan", "Initials": "SMH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy, Department of Pharmaceutics, Universiti Teknologi, Mara, Selangor, Malaysia."}], "LastName": "Hussain", "ForeName": "Zahid", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Medicinal, Aromatic and Poisonous Plants Research Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}], "LastName": "Ullah", "ForeName": "Riaz", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Medicinal, Aromatic and Poisonous Plants Research Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Phytochemistry Department, National Research Center, Dokki, Giza, Egypt."}], "LastName": "Shahat", "ForeName": "Abdelaaty Abdelaziz", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical Engineering, College of Engineering, Al-Muzahmeiah Branch, King Saud University, Riyadh, Saudi Arabia."}], "LastName": "Ibrahim", "ForeName": "Khalid", "Initials": "K"}], "PublicationTypeList": ["Comparative Study", "Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Drug Des Devel Ther", "NlmUniqueID": "101475745", "ISSNLinking": "1177-8881"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents, Non-Steroidal"}, {"RegistryNumber": "0", "NameOfSubstance": "Excipients"}, {"RegistryNumber": "144O8QL0L1", "NameOfSubstance": "Diclofenac"}, {"RegistryNumber": "RPK779R03H", "NameOfSubstance": "aceclofenac"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["administration & dosage", "chemistry", "pharmacology"], "DescriptorName": "Anti-Inflammatory Agents, Non-Steroidal"}, {"QualifierName": [], "DescriptorName": "Area Under Curve"}, {"QualifierName": [], "DescriptorName": "Biological Availability"}, {"QualifierName": ["methods"], "DescriptorName": "Chemistry, Pharmaceutical"}, {"QualifierName": ["administration & dosage", "analogs & derivatives", "chemistry", "pharmacology"], "DescriptorName": "Diclofenac"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": ["chemistry"], "DescriptorName": "Excipients"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Nanoparticles"}, {"QualifierName": [], "DescriptorName": "Particle Size"}, {"QualifierName": [], "DescriptorName": "Rabbits"}, {"QualifierName": [], "DescriptorName": "Solubility"}, {"QualifierName": [], "DescriptorName": "Toxicity Tests, Acute"}], "CoiStatement": "Disclosure The authors report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Sahu BP, Das MK. Nanosuspension for enhancement of oral bioavailability of felodipine. Appl Nanosci. 2014;4(2):189\u2013197."}, {"Citation": "Dizaj SM, Vazifehasl Z, Salatin S, Adibkia K, Javadzadeh Y. Nanosizing of drugs: effect on dissolution rate. Res Pharm Sci. 2015;10(2):95\u2013108.", "ArticleIdList": ["PMC4584458", "26487886"]}, {"Citation": "Sabzevari A, Adibkia K, Hashemi H, et al. Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies. Eur J Pharm Biopharm. 2013;84(1):63\u201371.", "ArticleIdList": ["23295645"]}, {"Citation": "Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785\u2013796.", "ArticleIdList": ["15340388"]}, {"Citation": "Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59(7):631\u2013644.", "ArticleIdList": ["17601629"]}, {"Citation": "Sinha B, M\u00fcller RH, M\u00f6schwitzer JP. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 2013;453(1):126\u2013141.", "ArticleIdList": ["23333709"]}, {"Citation": "Salazar J, M\u00fcller RH, M\u00f6schwitzer JP. Combinative particle size reduction technologies for the production of drug nanocrystals. J Pharm (Cairo) 2014;2014:265754.", "ArticleIdList": ["PMC4590828", "26556191"]}, {"Citation": "Xia D, Quan P, Piao H, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation\u2013ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40(4):325\u2013334.", "ArticleIdList": ["20417274"]}, {"Citation": "Reverchon E. Supercritical antisolvent precipitation of micro-and nanoparticles. J Supercritical Fluids. 1999;15(1):1\u201321."}, {"Citation": "Pathak P, Meziani MJ, Desai T, Sun YP. Formation and stabilization of ibuprofen nanoparticles in supercritical fluid processing. J Supercritical Fluids. 2006;37(3):279\u2013286."}, {"Citation": "Li H, Wang J, Bao Y, Guo Z, Zhang M. Rapid sonocrystallization in the salting-out process. J Crystal Growth. 2003;247(1):192\u2013198."}, {"Citation": "Louhi-Kultanen M, Karjalainen M, Rantanen J, Huhtanen M, Kallas J. Crystallization of glycine with ultrasound. Int J Pharm. 2006;320(1):23\u201329.", "ArticleIdList": ["16759826"]}, {"Citation": "De Castro ML, Priego-Capote F. Ultrasound-assisted crystallization (sonocrystallization) Ultrason Sonochem. 2007;14(6):717\u2013724.", "ArticleIdList": ["17254828"]}, {"Citation": "Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008;36(1):43\u201348.", "ArticleIdList": ["18337220"]}, {"Citation": "Douroumis D, Fahr A. Nano-and micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique. Eur J Pharm Biopharm. 2006;63(2):173\u2013175.", "ArticleIdList": ["16621482"]}, {"Citation": "Lindfors L, Forss\u00e9n S, Westergren J, Olsson U. Nucleation and crystal growth in supersaturated solutions of a model drug. J Colloid Interface Sci. 2008;325(2):404\u2013413.", "ArticleIdList": ["18561941"]}, {"Citation": "Mutalik S, Anju P, Manoj K, Usha AN. Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach. Int J Pharm. 2008;350(1):279\u2013290.", "ArticleIdList": ["17945447"]}, {"Citation": "Soni T, Nagda C, Gandhi T, Chotai N. Development of discriminating method for dissolution of aceclofenac marketed formulations. Dissolution Technol. 2008;15(2):31."}, {"Citation": "Tran TT, Tran PH, Nguyen MN, et al. Amorphous isradipine nanosuspension by the sonoprecipitation method. Int J Pharm. 2014;474(1):146\u2013150.", "ArticleIdList": ["25138256"]}, {"Citation": "Khan S, Matas Md, Zhang J, Anwar J. Nanocrystal preparation: low-energy precipitation method revisited. Crystal Growth Des. 2013;13(7):2766\u20132777."}, {"Citation": "Shah SMH, Ullah F, Khan S, et al. Smart nanocrystals of artemether: fabrication, characterization, and comparative in vitro and in vivo antimalarial evaluation. Drug Des Devel Ther. 2016;10:3837\u20133850.", "ArticleIdList": ["PMC5125812", "27920499"]}, {"Citation": "Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanoparticle Res. 2008;10(5):845\u2013862."}, {"Citation": "Thakkar H, Nangesh J, Parmar M, Patel D. Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system. J Pharm Bioallied Sci. 2011;3(3):442\u2013448.", "ArticleIdList": ["PMC3178953", "21966167"]}, {"Citation": "No OT. 423: acute oral toxicity-acute toxic class method. OECD guidelines for the Testing of Chemicals (Section 4: Health Effects) 2001:1\u201314."}, {"Citation": "Collier H, Dinneen L, Johnson CA, Schneider C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br J Pharmacol Chemother. 1968;32(2):295\u2013310.", "ArticleIdList": ["PMC1570212", "4230818"]}, {"Citation": "Shah S, Ullah F, Khan S, Shah S, Sadiq A. Combinative precipitation ultrasonication approach for fabrication for stable artemisinin nanosuspension. Am Eurasian J Agric Environ Sci. 2016;16(2):390\u2013401."}, {"Citation": "Lonare AA, Patel SR. Antisolvent crystallization of poorly water soluble drugs. Int J Chem Eng Appl. 2013;4(5):337."}, {"Citation": "Kipp JE, Wong JCT, Doty MJ, Werling J, Rebbeck CL, Brynjelsen S. 6884436 B2. Method for preparing submicron particle suspensions: Google Patents US. 2005 Apr 26;"}, {"Citation": "Bunjes H, Koch MH, Westesen K. Effect of particle size on colloidal solid triglycerides. Langmuir. 2000;16(12):5234\u20135241."}, {"Citation": "Valleri M, Mura P, Maestrelli F, Cirri M, Ballerini R. Development and evaluation of glyburide fast dissolving tablets using solid dispersion technique. Drug Dev Ind Pharm. 2004;30(5):525\u2013534.", "ArticleIdList": ["15244088"]}, {"Citation": "O\u2019Mahony M, Leung AK, Ferguson S, Trout BL, Myerson AS. A process for the formation of nanocrystals of active pharmaceutical ingredients with poor aqueous solubility in a nanoporous substrate. Org Process Res Dev. 2014;19(9):1109\u20131118."}, {"Citation": "Ali HS, York P, Ali AM, Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J Control Release. 2011;149(2):175\u2013181.", "ArticleIdList": ["20946923"]}, {"Citation": "Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;63(6):456\u2013469.", "ArticleIdList": ["21315781"]}, {"Citation": "Freitas C, M\u00fcller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN\u2122) dispersions. Inte J Pharm. 1998;168(2):221\u2013229."}, {"Citation": "Jacobs C, M\u00fcller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002;19(2):189\u2013194.", "ArticleIdList": ["11883646"]}, {"Citation": "Prabu SL, Sharavanan S, Govindaraju S, Suriyaprakash T. Formulation development of aceclofenac nanosuspension as an alternative approach for improving drug delivery of poorly soluble drugs. Int J Pharm Sci Nanotechnol. 2013;6(3):2145\u20132153."}, {"Citation": "Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 2015;10(1):13\u201323."}, {"Citation": "Junghanns J, M\u00fcller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295\u2013309.", "ArticleIdList": ["PMC2626933", "18990939"]}, {"Citation": "Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharma. 1989;51(1):9\u201317."}]}], "History": [{"Year": "2017", "Month": "9", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "9", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "5", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "8", "Day": "23"}], "PublicationStatus": "epublish", "ArticleIdList": ["28860715", "PMC5574597", "10.2147/DDDT.S140626", "dddt-11-2443"]}}]}